Strides Pharma Science Limited has announced the completion of a routine cGMP inspection by the United States Food and Drug Administration (USFDA) at its flagship manufacturing unit in Bangalore. The inspection, which took place from May 12, 2026, to May 20, 2026, resulted in the issuance of a Form 483 containing five observations. The company has committed to addressing these findings within the regulatory timeframe.
Inspection Outcome
The company successfully concluded a routine current Good Manufacturing Practices (cGMP) audit at its primary facility in Bangalore. The inspection process spanned over a week, running from May 12, 2026, to May 20, 2026. Following the review of operations, the USFDA issued a Form 483 report, which serves to notify company management of concerns regarding conditions or practices that may indicate potential violations of quality standards.
Next Steps for Compliance
The report issued by the agency highlighted five specific observations that require attention. Strides Pharma Science Limited is currently preparing a formal response to these items. The management has confirmed that they will address the concerns noted in the report within the stipulated timeframe to ensure continued compliance with international quality and safety benchmarks. The company has assured stakeholders that it will provide further updates as the matter progresses.
Source: BSE
